Participated · Equity · Feb 2025

BEKhealth, based in Research Triangle Park, NC, provides an AI-powered chart abstraction and patient-matching platform that extracts structured and unstructured data from electronic medical records (EMRs). The technology integrates EHR data to optimize population feasibility and rapidly identify clinically qualified participants for clinical research. Its platform supports organizations conducting clinical trials, observational research, and real-world evidence generation by improving protocol design and participant identification. The company announced customer growth in 2024 and now counts clients such as Avacare Clinical Research Network, Biopharma Informatics, Chemidox, Elixia Health, Javara, Om Research and others. BEKhealth raised $4M in funding and intends to use the proceeds to continue expanding its customer base and product offering. The company highlights its focus on expanding commercial adoption and enhancing its AI-driven capabilities to better serve research sponsors and sites. BEKHealth offers an AI-powered clinical research software platform that ingests and processes both structured and unstructured EMR data to drive feasibility assessments, site selection, precision patient matching, and care coordination. Its machine learning models combine more than 400 unique medical libraries and 70,000 research protocols with an interoperable clinical data model to power automated, daily identification of protocol-eligible patients. The platform is positioned to accelerate patient enrollment, cut timelines, and improve outcomes for sites and CROs while addressing cumbersome workflows and data access challenges. BEKHealth says its tools are increasingly in demand amid a more virtual healthcare environment and growing use of analytics in clinical research. The company is privately held, venture-backed, and based in Connecticut, and plans to use new funding to grow its team and expand availability and adoption of its platform.

Participated · Equity · Nov 2021

PierianDx builds assay-agnostic interpretation technology and services to help providers, laboratories, and medical centers run next-generation sequencing (NGS) testing on site. The company pairs advanced interpretation software with a comprehensive genomic knowledgebase to empower clinicians to understand genetic variation and inform treatment decisions. PierianDx partners with industry leaders and medical facilities worldwide as they build or expand precision medicine programs. The firm was founded in 2014 as a technology-transfer spinout from Washington University in St. Louis and is headquartered in St. Louis. Management says the business is expanding commercially as more healthcare organizations seek to internalize NGS testing capabilities. The recent financing is intended to fund commercial expansion and continued product and team development to bring genomics into more clinical settings. PierianDx offers a SaaS clinical genomics informatics platform that enables the practice of clinical next-generation sequencing (NGS) as a standard of care and supports advanced molecular diagnostic laboratories. The company also operates a CAP- and CLIA-accredited laboratory and provides integrated reporting and decision-support across the clinical care spectrum. PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Leadership emphasizes adding clinical expertise and resources to drive adoption of clinical NGS globally. Management plans to accelerate commercial expansion across the U.S. and international markets including Europe, Asia, Australia, and Latin America. PierianDx was founded in 2014 out of Washington University in St. Louis. PierianDx provides genomic software and services to enable data-driven personalized medicine. Its flagship platform, Clinical Genomicist Workstation (CGW), delivers data-driven workflows for health systems, academic medical centers, and commercial labs to support genomic analysis, interpretation and reporting. Led by CEO Ted Briscoe, the company focuses on improving patient outcomes through precise genomic analysis. PierianDx said it will use the new funding to accelerate product development and expand sales, marketing and operations. The company raised $9.25M in a Series A to support these initiatives.